Optimizing the use of daratumumab in AL amyloidosis

2 Views

07/08/23

Camille Vanessa Edwards, MD, Boston University School of Medicine, Boston, MA, outlines strategies to optimize the tolerability of daratumumab-based therapy in patients with AL amyloidosis, including administering daratumumab subcutaneously, simplifying pre-medications to decrease the risk of infusion-related reactions, and shortening the observation period. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.